

**CLINICAL CHARACTERISTICS OF PATIENTS WITH ENDOMETRIAL  
CANCER AND MODERN DIAGNOSIS METHODS**

**Mamarasulova D. Z\*; Validova A. F\*\*; Turabjonova D\*\*\***

\*Doctor of Science,  
Head of the Department of Oncology and Radiology,  
Andijan State Medical Institute,  
UZBEKISTAN  
Email id: dilya2580559@gmail.com

\*\*Head of the Department of Oncogynecology,  
Republican Specialized Scientific and Practical,  
Medical Center of oncology and radiology of the Andijan branch,  
UZBEKISTAN

\*\*\*Master's Student,  
Department of Oncology,  
Andijan State Medical Institute,  
UZBEKISTAN

**DOI: 10.5958/2249-7315.2022.00356.2**

---

**ABSTRACT**

*Over the past two decades and in most countries of the world, there has been a clear trend toward an increase in the frequency of hormone-dependent tumors, and first of all, these are precancerous conditions and endometrial cancer. Questions of etiology, pathogenesis and diagnosis of pathological processes of the endometrium remain open. The proposed algorithm for the diagnosis of patients with endometrial hyperplastic processes and endometrial cancer showed the high efficiency of hormone therapy in endometrial hyperplastic processes and endometrial cancer.*

**KEYWORDS:** *Endometrial Cancer, Endometrial Hyperplastic Processes, Diagnosis.*

---

**REFERENCES**

1. Assasi N., Blackhouse G., Campbell K. DNA Mismatch repair deficiency tumour testing for patients with colorectal cancer: a health technology assessment. Canadian Agency for Drugs, Technologies in Health. Optimal Use Report, vol. 5, no. 3b. Ottawa, Canada, 2016. PMID: 27631047.
2. Baker J, Obermair A, Gebiski V, et al. Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature. // GynecolOncol. 2012 Apr;125(1):263-70. KP460 26
3. Barzi A., Sadeghi S., Kattan M.W., Meropol N.J. Comparative effectiveness of screening strategies for Lynch syndrome. J. Natl. Cancer Inst. 2015; 107: djv005. DOI: 10.1093/jnci/djv005.
4. Braun M.M., Overbeek-Wager E.A., Grumbo R.J. Diagnosis and management of endometrial cancer. Am. Family Phys. 2016, 93 (6), 468–474. PMID: 26977831.
5. Burk J.R., Lehman H.F., Wolf F.S. Inadequacy of papanicolaou smears in the detection of

endometrial cancer. *N. Engl. J. Med.* 1974; 291 (4): 191–192. DOI: 10.1056/NEJM197407252910408.

6. Burton ER, Sorosky JI. Recognition and Therapeutic Options for Malignancy of the Cervix and Uterus *ObstetGynecol Clin North Am*2017; 44 (2): 195–206.
7. Cade TJ., Quinn MA., McNally OM. et al. Predictive value of magnetic resonance imaging in assessing myometrial invasion in endometrial cancer: is radiological staging sufficient for planning conservative treatment? *Int J Gynecol Cancer.* – 2010. – V. 20, N 7. – P. 1166–9.
8. Charalampakis V, Tahrani A, Helmy A et al. Polycystic ovary syndrome and endometrial hyperplasia:an overview of the role of bariatric surgery in female fertility. *Eur J ObstetGynecolReprod Biol*2016; 207: 220–6.
9. Cheng W.F., Lin H.H., Torng P.L., Huang S.C. Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients. *Gynecol. Oncol.* 1997; 66 (2): 233–237. DOI: 10.1006/gyno.1997.4739.
10. Cibula D, Gompel A, Mueck AO et al. Hormonal contraception and risk of cancer. *Hum Reprod Update* 2010; 16 (6): 631–50.
11. Clark T.J., Voit D., Gupta J.K. et al. Accuracy of hysteroscopy in the diagnosis of endometrial cancer and hyperplasia: a systematic quantitative review. *JAMA.* 2002; 288 (13): 1610–1621. DOI: 10.1001/jama.288.13.1610.
12. Clark TJ, Stevenson H. Endometrial Polyps and Abnormal Uterine Bleeding (AUB-P): What is the relationship, how are they diagnosed and how are they treated? *Best Pract Res Clin ObstetGynaecol* 2016 (40): 89–104.
13. Clement NS, Oliver TR, Shiwani H et al. Metformin for endometrial hyperplasia: a Cochrane protocol.*BMJ Open* 2016; 6 (8): e013385.